NAS:SRPT (USA) Also Trade In: Brazil Germany UK

Sarepta Therapeutics Inc $ 138 -2.79 (-1.98%)

Avg Vol (1m):
Market Cap $:
10.93 Bil
Enterprise Value $:
9.63 Bil
P/E (TTM):
Warning! GuruFocus has detected 1 Severe warning sign with SRPT. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

SRPT News and Headlines - Sarepta Therapeutics Inc

GuruFocus Articles Total 23
  • 1
  • 2

Biotech's shares trading near all-time high of $172. It is also working on Covid-19 treatment

On the heels of research deals with two small biotechs, shares of Sarepta Therapeutics Inc. (SRPT) hit their all-time high of more than $172 on June 23.

The share price of the Cambridge, Massachusetts-based biopharmaceutical company has doubled since mid-March. It has a market cap of more than $13 billion.

Sarepta has made a host of deals in the past several years that have made gene therapy a key part of its business, which had been dominated by drugs for muscular dystrophy. One of those pacts, with Roche (RHHBY), could be worth more than $3 billion.

Sarepta currently has a

165 Views    Barry Cohen    2020-06-23 19:05
3 of the fund's new holdings are biotech companies

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2019 portfolio late last week, listing four new holdings.

Managed by Jean Hynes, the fund invests in a variety of health care-related stocks from around the world in order to achieve long-term capital appreciation. She picks stocks of companies that have high-quality balance sheets, strong management teams and the potential for new products that will generate consistently above-average revenue and earnings growth.

Based on these criteria, the fund established positions in Reata Pharmaceuticals Inc. (RETA), Ascendis Pharma AS (ASND), Sarepta Therapeutics Inc. (SRPT) and Notre Dame Intermedica

345 Views    Sydnee Gatewood    2020-02-04 16:28
Companies with gene therapy capabilities are becoming more attractive to members of Big Pharma, who are eager to add the technology to their portfolios

Are UniQure (QURE), Ultragenys (RARE) and Sarepta Therapeutics (SRPT) among the next dominoes that could fall as Big Pharma looks to acquire companies with expertise in gene therapy? Speculation has heated up after the announcement that Astellas Pharma (ALPMY) will pay $3 billion to buy Audentes Therapeutics (BOLD).

SVB Leerink analyst Mani Froohar thinks more takeovers are in the making. Yahoo Finance reported that in a note to clients, Froohar said the latest deal “may signal big pharma's optimism towards M&A (mergers and acquisitions) and that the gene therapy sector remains an appealing hotbed for innovative and value-creating

87 Views    Barry Cohen    2019-12-05 21:32
Overview of stocks that are 'triple buys'

According to the Triple Buys Screener, a GuruFocus Premium feature, three stocks where gurus, insiders and the company itself are buying shares are Sarepta Therapeutics Inc. (SRPT), Gulfport Energy Corp. (GPOR) and F.N.B. Corp. (FNB).

CNBC reported Goldman Sachs Group Inc. (GS), a large bank holding of Warren Buffett (Trades, Portfolio)’s Berkshire Hathaway Inc. (BRK.A)(BRK.B), said in a note that corporate buybacks are “plummeting as companies tighten their purse strings.” Despite this, the investment bank said that while the amount spent on company share buybacks this year declined 17% from the

821 Views    James Li    2019-10-21 21:47
The FDA just blocked Sarepta's new Duchenne muscular dystrophy drug. Sarepta calls it 'surprising.' But is it really?

Sarepta Therapeutics (SRPT) was just hit with a hefty dose of regulatory reality. Its new Duchenne muscular dystrophy drug golodirsen just received a complete response letter (CRL) from the Food and Drug Administration, which means it will have to go back to the drawing board and perhaps initiate a new pivotal trial if it has any chance of reaching the market.

The exact details of the CRL are confidential, but scant reports based on word from the company assert that there were two reasons for the rejection. The first is infusion port infection as the drug is administered through

79 Views    Matt Winkler    2019-08-21 15:40
Insiders invest in Capri Holdings, General Electric, Sarepta Therapeutics, Ryman Hospitality Properties and Axogen

According to GuruFocus insider data, these are the largest CEO buys of the past week.

Capri Holdings CEO bought 363,000 shares

Capri Holdings Ltd. (CPRI) Chairman and CEO John D. Idol bought 363,000 shares on Aug. 15 for a price of $27.48. The share price has risen 2.77% since then.

Capri Holdings, formerly Michael Kors Holdings Ltd., designs and manufactures apparel, footwear and accessories (primarily handbags). Products are positioned as luxury goods and sold under three brands: Michael Kors, Versace and Jimmy Choo. The company has a market cap of $4.28 billion. Its shares traded at $28.24 with a price-earnings

117 Views    Joy Hu    2019-08-18 20:59
There are known knowns, known unknowns and unknown unknowns

The biotechnology and pharmaceutical industry has something for everyone. Whether you are looking for a mature dividend aristocrat like GlaxoSmithKline (GSK) or a small-cap upstart like Sarepta (SRPT) that can double in value overnight, the sector will provide an option that suits your preferred risk-reward profile. Due to the technical nature of the industry, investing in these companies differs from investing in more conventional businesses, especially when we are talking about the smaller-cap biotechs.

These are companies that typically have only one or two drugs on the market, and frequently do not even have that, if they

71 Views    Stepan Lavrouk    2019-05-16 14:49
Fund releases 1st-quarter portfolio

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) released its first-quarter portfolio this week, listing five new holdings.

Managed by Jason Kritzer and Samantha Pandolfi, the Boston-based fund invests heavily in the health care space. The portfolio managers look around the world for securities that are not only reasonably priced, but which they believe will grow in value over time.

Based on these criteria, the fund opened positions in Alexion Pharmaceuticals Inc. (ALXN), Fisher & Paykel Healthcare Corp. Ltd. (NZSE:FPH), Alnylam Pharmaceuticals Inc. (ALNY), Argenx SE (ARGX) and Sarepta Therapeutics Ltd. (SRPT) during the quarter.


386 Views    Sydnee Gatewood    2019-05-02 21:43
Insiders shed shares of Advanced Micro Devices, Sarepta Therapeutics

According to GuruFocus insider data, the recent chief financial officer sells were Advanced Micro Devices Inc. (AMD) and Sarepta Therapeutics Inc. (SRPT).

Advanced Micro Devices CFO sold 130,000 shares

Senior Vice President, CFO and Treasurer Devinder Kumar sold 130,000 shares for $19.82 per share on Jan. 29. Since then, the share price has climbed 16.3%. Advanced Micro Devices has a market cap of $23.04 billion and its shares traded around $23.05. The company has a price-earnings ratio of 72.03 and a price-sales ratio of 3.98.

Advanced Micro Devices announced its fourth-quarter results with revenue of $1.42 billion and gross profit

37 Views    Myra Ramdenbourg    2019-02-11 16:21
Insiders dump shares of Twitter, Sarepta Therapeutics

According to GuruFocus Insider Data, the recent chief financial officer sells were: Twitter Inc. (TWTR) and Sarepta Therapeutics Inc. (SRPT).

Twitter CFO sold 6,000 shares

CFO Ned D. Segal sold 6,000 shares for $31.67 per share on Jan. 8. Since then, the stock price has risen 7.17%. Twitter has a market cap of $25.84 billion and its shares were traded around $33.94. The company has a price-earnings ratio of 25.14 and a price-sales ratio of 9.06.

Twitter announced its third-quarter results with revenue of $758.11 million and gross profit of $514.47 million, while net income was $789.18 million. The 2017

154 Views    Myra Ramdenbourg    2019-02-05 15:08
Details the CEO buys this past week from the following companies: Tesla, Sarepta Therapeutics, Hasbro, PacWest Bancorp and Belden

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

Tesla CEO bought 29,844 shares

Tesla Inc. (TSLA) CEO and 10% Owner Elon Musk bought 29,844 shares on Oct. 29 at a price of $334.98. The price of the stock has increased by 3.41% since.

Tesla is a vertically integrated sustainable energy company. It designs, develops, manufactures and sells high-performance fully electric vehicles and electric vehicle powertrain components. The company has a market cap of $59.10 billion. Its shares traded at $346.41 as of Nov. 2.

Net income for the third quarter of 2018 was

67 Views    Joy Hu    2018-11-05 15:17
Recent sells from company CFOs

According to GuruFocus Insider Data, the recent CFO sells were: Sarepta Therapeutics Inc. (SRPT), PayPal Holdings Inc. (PYPL) and Costco Wholesale Corp (COST).

Sarepta Therapeutics Inc.: EVP, CFO and CBO Sandesh Mahatme sold 107,524 shares

Executive Vice President, Chief Finanial Officer and Chief Business Officer Sandesh Mahatme sold 107,524 shares for $127.74 per share on Oct. 24. Since then, the stock price has increased by 11.16%. Sarepta Therapeutics Inc. has a market cap of $9.49 billion and its shares were traded around $141.99. The company has a price-sales ratio of 37.68. Over the past five years, Sarepta Therapeutics

62 Views    Myra Ramdenbourg    2018-11-02 15:13
Competition is expected to be tough

After 16 years of development and $2.5 billion in investments, Alnylam Pharmaceuticals Inc. (ALNY) brought the world’s first RNAi treatment, known as Onpattro, to market.

Despite this accomplishment, the company did not see a significant jump in its stock following the Food and Drug Administration's approval. In fact, Alnylam is down approximately 6% over the last three months.


Despite the cold market reaction, it is clear Alnylam is promising long term for several reasons. First, RNAi therapies in general show tremendous promise in treating diseases. Second, Alnylam is in the process of

65 Views    Maxwell Koobatian    2018-08-20 15:19
Insiders invest in Penn National Gaming, Sarepta Therapeutics, News Corp., e.l.f. Beauty and New Media Investment Group

According to GuruFocus insider data, these are the largest CEO buys of the past week.

Penn National Gaming CEO bought 100,000 shares

Penn National Gaming Inc. (PENN) CEO Timothy J. Wilmott bought 100,000 shares on Aug. 15 at a price of $30.85 per share. The stock price has increased by 7.13% since then.

The casino operator has a market cap of $3.04 billion. Its shares traded at $33.05 with a price-earnings ratio of 5.67 as of Aug. 17.

Net income for the second quarter of 2018 was $54 million, compared to $17.1 million in the prior-year period.

Director Jane Scaccetti

90 Views    Joy Hu    2018-08-20 14:50
Sarepta Therapeutics has exploded higher since last year on the hopes that its Duchenne muscular dystrophy drug is effective and insurance will keep covering it. Much like Tesla, its stock price is fu

Sarepta Therapeutics (SRPT) has been one of the most rewarding biotech investments since the beginning of 2017. I consider it the Tesla Inc. (TSLA) of the biotech industry. That’s a good thing as long as investors remain infatuated with the idea of a new company with a revolutionary product that has not yet proven itself in the marketplace. Could the company actually make money? Of course, but that's not currently why its market caps is so high.

Let’s flesh out the analogy further. Tesla is the first company to successfully introduce electric cars to the mainstream. But despite its success

245 Views    Matt Winkler    2018-03-12 16:34
Perceptive Advisors already has a stake in new IPO in biotech

In the biotech space, Perceptive Advisors is about as close to a household name as you can get.

The fund, headed up by biotech guru Joseph Edelmen, who made the institutional hedge fund rich list for the first time last year, is a life sciences focus hedge fund renowned for its ability to uncover young biotech companies and fund them to the successful commercialization of their pipeline.

It's no secret that traders and investors in the health care sector look to piggyback the positions of Perceptive – the fund is about as closely watched as they come in

163 Views    George Ronan    2017-05-04 18:59
Largest 4th-quarter sales by the investor.

Steven Cohen (Trades, Portfolio) is a billionaire hedge fund investor and the founder of SAC Capital Advisors, a Stamford, Connecticut-based hedge fund which he continues to manage. During the fourth quarter the guru sold shares in the following stocks:

The guru reduced his position in Alphabet Inc. Class AÂ (GOOG) by 71.59% with an impact of -1.7% on the portfolio.

The company through its subsidiary Google Inc. is engaged in improving the ways people connect with information and products including Search, Android, YouTube, Apps, Maps and Ads. It also produces internet-connected home devices and provides internet

519 Views    Tiziano Frateschi    2017-03-07 21:04
Panel does not recommend approval of muscular dystrophy treatment drug

On the news that a Food and Drug Administration advisory committee had declined to recommend the approval of eteplirsen, an experimental drug designed to treat Duchenne muscular dystrophy (DMD), the price of shares of Sarepta Therapeutics Inc. (SRPT) fell by nearly half in early trading Tuesday.

The committee’s vote Monday night was 7-3 against recommending approval with three abstentions.

“The FDA is not obliged to follow the advice of its advisory panels,” Reuters reported, “but typically does so."

Sarepta, a Cambridge, Massachusetts-based medical research and drug development company, sold for $8.58 per share, Sarepta’s lowest share price since August

783 Views    David Goodloe    2016-04-26 22:15

On May 19, Sarepta Therapeutics Inc (NASDAQ: SRPT) announced plans to complete a New Drug Application (NDA) for eteplirsen, Sarepta’s lead product candidate. SRPT shares surged 44% to $23 following the news. Eteplirsen is a treatment for Duchenne muscular dystrophy and Sarepta plans to complete the application by mid-2015.

Sarepta’s interim CEO Edward Kaye, M.D., noted, “The initiation of our NDA submission for eteplirsen marks a significant milestone for the Duchenne community, and we look forward to completing the submission by the middle of the year and to continuing to work with the [FDA] towards

666 Views    TipRanks    2015-05-20 22:28

Yahoo! Inc. (YHOO) shares increased more than 2% to $41.85 per share in pre-market trading on Wednesday after the company confirmed plans to spin off Alibaba holdings despite IRS comments that might complicate the tax status of the move.

Sarepta Therapeutics Inc (SRPT) shares soared over 50% to $24.60 in pre-market trading after the pharmaceutical company announced that it will begin the process of gaining regulatory approval for eteplirsen; a therapy for Duchenne muscular dystrophy.

Time Warner Cable Inc (WC) shares increased 2.5% to $162 in pre-market trading following news that the cable company has been approached

560 Views    TipRanks    2015-05-20 21:24

Headlines Total 192
  • 1
  • 2

2020-10-12 $ 142.87 (-0.49%)
2020-10-01 $ 140.43 (-0.6%)
2020-09-28 $ 143.2 (-0.56%)
2020-09-22 $ 146.31 (2.43%)
2020-09-15 $ 142.8 (3.1%)
2020-09-14 $ 138.5 (5.98%)
2020-09-11 $ 127.12 (-2.58%)
2020-09-10 $ 130.49 (1.17%)
2020-09-04 $ 132.75 (-2.88%)
2020-09-01 $ 146.42 (-0.71%)
2020-08-26 $ 148.85 (2.7%)
2020-08-25 $ 144.94 (2.65%)
2020-08-06 $ 154.42 (-2.81%)
2020-08-05 $ 158.89 (1.38%)
2020-08-04 $ 156.73 (-0.95%)
2020-08-01 $ 153.52 (-0.37%)
2020-07-29 $ 150 (-3.53%)
2020-07-24 $ 158.63 (-1.88%)
2020-07-15 $ 169.66 (1.74%)
2020-07-13 $ 161.98 (-4.05%)
2020-07-02 $ 162.75 (-1.77%)
2020-07-01 $ 160.34 (-1.46%)
2020-06-30 $ 160.34 (-1.46%)
2020-06-29 $ 162.71 (0.05%)
2020-06-26 $ 162.63 (-2.8%)
2020-06-24 $ 163.63 (-3.07%)
2020-06-23 $ 168.81 (-1.68%)
2020-06-22 $ 171.7 (1.71%)
2020-06-19 $ 168.82 (2.18%)
2020-06-18 $ 165.22 (1.1%)
2020-06-16 $ 160.22 (1.39%)
2020-06-15 $ 158.02 (-0.52%)
2020-06-12 $ 158.85 (3.42%)
2020-06-09 $ 155.65 (-2.52%)
2020-06-08 $ 159.68 (7.9%)
2020-06-06 $ 147.99 (2.06%)
2020-06-05 $ 147.99 (2.06%)
2020-06-03 $ 149.04 (-1.3%)
2020-05-30 $ 152.27 (-0.48%)
2020-05-28 $ 153 (-2.65%)
2020-05-18 $ 146.77 (3.91%)
2020-05-15 $ 141.25 (11.18%)
2020-05-13 $ 132.89 (-2.16%)
2020-05-11 $ 135.83 (6.12%)
2020-05-07 $ 123.61 (0.85%)
2020-05-06 $ 122.57 (2.62%)
2020-05-01 $ 117.88 (0.67%)
2020-04-29 $ 117.09 (-2.17%)
2020-04-28 $ 119.69 (-1.99%)
2020-04-15 $ 112.09 (-0.85%)
2020-04-14 $ 113.05 (1.29%)
2020-04-01 $ 97.82 (-0.71%)
2020-03-27 $ 94.44 (-4.62%)
2020-02-29 $ 114.47 (6.32%)
2020-02-27 $ 107.67 (-5.25%)
2020-02-19 $ 121.9 (-0.72%)
2020-02-01 $ 115.96 (-1.58%)
2020-01-13 $ 124.63 (-3.4%)
2020-01-06 $ 131.45 (1.29%)
2020-01-01 $ 129.04 (0.19%)
2019-12-23 $ 135.58 (7.46%)
2019-12-18 $ 131.47 (-2.87%)
2019-12-13 $ 132.05 (31.43%)
2019-11-30 $ 112.49 (1.42%)
2019-11-27 $ 108.89 (1.68%)
2019-11-14 $ 97.41 (-3.55%)
2019-11-12 $ 99.95 (5.45%)
2019-11-06 $ 93.5 (2.96%)
2019-11-01 $ 83.06 (-1.02%)
2019-10-25 $ 85.75 (2.66%)
2019-10-24 $ 83.53 (-0.7%)
2019-10-21 $ 86.62 (0.99%)
2019-10-16 $ 88.05 (2.74%)
2019-10-11 $ 83.48 (0.38%)
2019-10-09 $ 80.78 (0.32%)
2019-10-08 $ 80.52 (-0.54%)
2019-10-04 $ 88.25 (8.5%)
2019-10-03 $ 77.69 (1.52%)
2019-10-02 $ 76.53 (1.61%)
2019-10-01 $ 75.32 (0.43%)
2019-09-25 $ 75.96 (-2.3%)
Total 192
  • 1
  • 2